|
 The National Institute for Health and Care Excellence (NICE) said on
Monday it was now recommending Zytiga, which is sold by Johnson &
Johnson, following the submission of new evidence on the drug's
benefits.
The current list price of Zytiga is 2,930 pounds ($4,217) for 120
tablets and NICE said this was expected to fall to 2,300 by the time
its final guidance was published. J&J has also agreed to rebate the
cost of any tablets needed beyond 10 months of treatment.
Paul Workman, chief executive of the Institute of Cancer Research in
London, whose scientists discovered the medicine, said the latest
NICE decision was good news but he criticized the agency for a
three-year delay in reaching the verdict.
“The answer today is the right one, but I would urge NICE to
implement the planned overhaul of its drug appraisal processes as
soon as possible to avoid repeated delays in getting the best, most
innovative treatments to patients," Workman said.
[to top of second column] |
(Reporting by Ben Hirschler, editing by Louise Heavens)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
